The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration
Open Access
- 28 June 2024
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 138, 112553
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancerClinical and Translational Medicine, 2022
- Overexpression of long non-coding RNA ACTA2-AS1 inhibits the viability, proliferation, migration and invasion of colorectal cancer cellsTissue and Cell, 2022
- Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathwaysBiochemical Pharmacology, 2022
- MAPK pathway activation selectively inhibits ASCL1-driven small cell lung canceriScience, 2021
- Epithelial-Mesenchymal Plasticity in Cancer Progression and MetastasisDevelopmental Cell, 2019
- Long noncoding RNA MNX1‐AS1 contributes to lung cancer progression through the miR‐527/BRF2 pathwayJournal of Cellular Physiology, 2019
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Mutation of EMG1 causing Bowen–Conradi syndrome results in reduced cell proliferation rates concomitant with G2/M arrest and 18S rRNA processing delayBBA Clinical, 2014
- Mutation of a Gene Essential for Ribosome Biogenesis, EMG1, Causes Bowen-Conradi SyndromeThe American Journal of Human Genetics, 2009
- Staging for Liver CancerClinics in Liver Disease, 2005